# Delos Capital

> Delos Capital is a VC fund in Central backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 12
- Last investment: Jun 2026
- Lead investor: 42%
- Last fund: Feb 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/delos-capital
- Website: http://www.delos.capital/

Delos Capital is a healthcare-focused fund, investing in growth platforms and relevant innovation in both therapeutic and medical technology areas. Delos Capital seeks to achieve returns by supporting these companies in their development and also helping to create additional value from collaboration between these companies.

## Contacts

5 contacts available for Delos Capital. Shizune tracks 2 team members at Delos Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/delos-capital-康禧全球投資基金?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 67% |
| Health Care | 4 | 33% |
| Therapeutics | 3 | 25% |
| Medical | 2 | 17% |
| Biopharma | 2 | 17% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 33% |
| Series B | 4 | 33% |
| Series C | 1 | 8% |
| Funding Round | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Henry Chen | Founder and Managing Partner | 7 | https://shizune.co/investors/profile/henry-chen-9c2b |
| Eric Huang | Partner | 2 | https://shizune.co/investors/profile/eric-huang-de8c |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rejoni | Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M | Venture - Series Unknown | Jun 16, 2026 |  |
| TRex Bio | TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M |  | Jan 27, 2026 |  |
| TRex Bio | TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M | Series B | Nov 13, 2024 |  |
| Averna Therapeutics | Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells. | $85M | Series A | Jun 25, 2024 |  |
| Sirius Therapeutics | Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases. | $60M | Series B | Oct 09, 2023 |  |
| Ostial Corporation | Ostial Corporation develops an ostial system designed to help overcome the challenges of aorto-ostial stenting. Ostial Corporation's system uses dual-balloon angioplasty catheter which is designed to conform to the ostium for stent apposition, allowing physicians to achieve maximal stent wall apposition after post-dilation. | $7.5M | Series C | Sep 16, 2022 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $75M | Series B | Nov 03, 2021 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $96M | Series B | Apr 12, 2021 |  |
| Curamir Therapeutics | Curamir is a Woburn, MA-based biotechnology company launched and incubated by Delos Capital with an initial academic licensing from SUNY. Through its proprietary miRNA engineering platform and insights into cancer biology, Curamir develops miRNA-based cancer therapeutics with enhanced safety, potency and stability. Its novel approach addressescurrent challenges associated with both chemoresistance in cancer and effective systemic delivery of miRNA mimics. |  | Series A | Sep 23, 2019 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $25M | Series A | Nov 27, 2018 |  |

10 of 12 investments shown.

## Co-investors
- [Soleus Capital](https://shizune.co/investors/profile/soleus-capital) — VC Fund, 4 deals together
- [CAM Capital](https://shizune.co/investors/profile/camcapital) — VC Fund, 3 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 3 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 3 deals together
- [Sixty Degree Capital](https://shizune.co/investors/profile/quantum-vista-capital) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Delos Capital invest in?

Delos Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Delos Capital?

Public channels for Delos Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Delos Capital?

The team at Delos Capital includes Henry Chen (Founder and Managing Partner) and Eric Huang (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co